Many drugs targeting TLR4 are already in clinical trials, and the two Food and Drug Administration (FDA)-approved drugs named Bacillus Calmette–Guerin (a vaccine used against tuberculosis) and monophosphoryl lipid A (MPLA; used for the treatment of bladder and cervical cancer) are available on the market [6]. This evidence concerns the gene TLR4 and cervical carcinoma.